India emerging as a key player in the global pharmaceutical supply chain
News: India’s Contract Research, Development, and Manufacturing Organization (CRDMO) industry is set to double from USD 7 billion to USD 14 billion by 2028, growing at a 14% CAGR, according to a Macquarie Equity Research report.
Regulatory support, rising pharmaceutical outsourcing, and global supply chain shifts are driving this growth. The US Biosecure Act could further accelerate expansion, potentially pushing the market to USD 22 billion by 2030.
India’s cost advantage (30-40% lower than Western counterparts), strong regulatory approvals (USFDA, EMA), and expertise in APIs and speciality chemicals make it a preferred destination for pharmaceutical outsourcing. As global firms reduce reliance on China, India is emerging as a key player in the pharmaceutical supply chain.
Source: The Economic Times
Join The Community
Recent News
-
India Seeks Interim Trade Deal with U.S. Ahead of July Tariff Implementation -
Blackstone to Invest ₹5127 Crore in Maharashtra to Develop 10 New Logistics and Industrial Parks -
GMR Hyderabad International Airport to Acquire Full Stake in ESR GMR Logistics Park for ₹41 Crore -
Trump New Executive Orders Could Impact Indian Pharma Exports, Alter Global Drug Supply Chains: Report -
Supply Chain Shifts Boost India, South Asia’s Industrial Growth: Report
1 Comment